| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.94 [0.27, 3.26] | | < 1 | | 52% | 2 studies (2/-) | 54.1 % | some concern | not evaluable | moderate | crucial | - |
| progression or deaths (PFS) | 0.73 [0.50, 1.05] | | < 1 | | 0% | 2 studies (2/-) | 95.7 % | some concern | not evaluable | moderate | important | - |
| objective responses (ORR) | 1.49 [0.18, 12.08] | | > 1 | | 80% | 2 studies (2/-) | 64.3 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
| AE (any grade) | 0.47 [0.04, 5.52] | | < 1 | | 0% | 2 studies (2/-) | 72.3 % | some concern | not evaluable | moderate | non important | - |
| AE (grade 3-4) | 1.79 [0.06, 56.03] | | < 1 | | 88% | 2 studies (2/-) | 37.2 % | some concern | not evaluable | moderate | non important | - |
| AE leading to death (grade 5) | 2.61 [0.57, 11.92] | | < 1 | | 0% | 2 studies (2/-) | 10.8 % | some concern | not evaluable | moderate | non important | - |
| AE leading to treatment discontinuation (any grade) | 0.63 [0.24, 1.67] | | < 1 | | 0% | 1 study (1/-) | 82.4 % | NA | not evaluable | | non important | - |
| SAE (any grade) | 1.71 [0.86, 3.43] | | < 1 | | 0% | 2 studies (2/-) | 6.4 % | some concern | not evaluable | moderate | non important | - |
| STRAE (any grade) | 0.92 [0.32, 2.65] | | < 1 | | 0% | 2 studies (2/-) | 56.3 % | some concern | not evaluable | moderate | non important | - |
| TRAE (any grade) | 0.59 [0.05, 6.90] | | < 1 | | 84% | 2 studies (2/-) | 66.1 % | some concern | not evaluable | moderate | non important | - |
| TRAE (grade 3-4) | 0.74 [0.02, 34.86] | | < 1 | | 83% | 2 studies (2/-) | 55.9 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to death (grade 5) | 1.02 [0.02, 52.03] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
| TRAE leading to discontinuation (any grade) | 1.02 [0.24, 4.26] | | < 1 | | 0% | 1 study (1/-) | 49.1 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Acute kidney injury TRAE (grade 3-4) | 2.05 [0.07, 62.21] | | < 1 | | 0% | 1 study (1/-) | 34.2 % | NA | not evaluable | | non important | - |
| Adrenal insufficiency TRAE (grade 3-4) | 2.05 [0.07, 62.21] | | < 1 | | 0% | 1 study (1/-) | 34.2 % | NA | not evaluable | | non important | - |
| Anaemia TRAE (grade 3-4) | 0.08 [0.00, 1.41] | | < 1 | | 0% | 1 study (1/-) | 95.6 % | NA | not evaluable | | non important | - |
| Asthenia TRAE (grade 3-4) | 0.25 [0.01, 5.61] | | < 1 | | 0% | 1 study (1/-) | 80.7 % | NA | not evaluable | | non important | - |
| Colitis TRAE (grade 3-4) | 2.05 [0.07, 62.21] | | < 1 | | 0% | 1 study (1/-) | 34.2 % | NA | not evaluable | | non important | - |
| Constipation TRAE (grade 3-4) | 0.50 [0.02, 15.30] | | < 1 | | 0% | 1 study (1/-) | 65.1 % | NA | not evaluable | | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.50 [0.02, 15.30] | | < 1 | | 0% | 1 study (1/-) | 65.1 % | NA | not evaluable | | non important | - |
| Dermatitis acneiform TRAE (grade 3-4) | 0.50 [0.02, 15.30] | | < 1 | | 0% | 1 study (1/-) | 65.1 % | NA | not evaluable | | non important | - |
| Diarrhoea TRAE (grade 3-4) | 1.02 [0.02, 52.03] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
| Dyspepsia TRAE (grade 3-4) | 0.50 [0.02, 15.30] | | < 1 | | 0% | 1 study (1/-) | 65.1 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 1.02 [0.02, 52.03] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
| Febrile neutropenia TRAE (grade 3-4) | 0.08 [0.00, 1.41] | | < 1 | | 0% | 1 study (1/-) | 95.6 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 2.05 [0.07, 62.21] | | < 1 | | 0% | 1 study (1/-) | 34.2 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 1.02 [0.02, 52.03] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 1.02 [0.02, 52.03] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
| Increased lipase level TRAE (grade 3-4) | 2.05 [0.07, 62.21] | | < 1 | | 0% | 1 study (1/-) | 34.2 % | NA | not evaluable | | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 1.02 [0.02, 52.03] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
| Leucopenia TRAE (grade 3-4) | 0.16 [0.01, 3.32] | | < 1 | | 0% | 1 study (1/-) | 87.8 % | NA | not evaluable | | non important | - |
| Nausea TRAE (grade 3-4) | 0.25 [0.01, 5.61] | | < 1 | | 0% | 1 study (1/-) | 80.7 % | NA | not evaluable | | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.09 [0.01, 1.76] | | < 1 | | 0% | 1 study (1/-) | 94.1 % | NA | not evaluable | | non important | - |
| Pneumonia TRAE (grade 3-4) | 1.02 [0.06, 16.62] | | < 1 | | 0% | 1 study (1/-) | 49.5 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 1.02 [0.02, 52.03] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
| Rash TRAE (grade 3-4) | 1.02 [0.06, 16.62] | | < 1 | | 0% | 1 study (1/-) | 49.5 % | NA | not evaluable | | non important | - |
| Stomatitis TRAE (grade 3-4) | 2.05 [0.07, 62.21] | | < 1 | | 0% | 1 study (1/-) | 34.2 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
| Arthralgia AE (grade 3-4) | 0.70 [0.01, 37.74] | | < 1 | | 0% | 1 study (1/-) | 56.9 % | NA | not evaluable | | non important | - |
| Back pain AE (grade 3-4) | 0.70 [0.01, 37.74] | | < 1 | | 0% | 1 study (1/-) | 56.9 % | NA | not evaluable | | non important | - |
| Constipation AE (grade 3-4) | 0.70 [0.01, 37.74] | | < 1 | | 0% | 1 study (1/-) | 56.9 % | NA | not evaluable | | non important | - |
| Cough AE (grade 3-4) | 0.70 [0.01, 37.74] | | < 1 | | 0% | 1 study (1/-) | 56.9 % | NA | not evaluable | | non important | - |
| Diarrhoea AE (grade 3-4) | 1.44 [0.04, 46.58] | | < 1 | | 0% | 1 study (1/-) | 42.0 % | NA | not evaluable | | non important | - |
| Dry skin AE (grade 3-4) | 0.70 [0.01, 37.74] | | < 1 | | 0% | 1 study (1/-) | 56.9 % | NA | not evaluable | | non important | - |
| Dyspnoea AE (grade 3-4) | 0.70 [0.01, 37.74] | | < 1 | | 0% | 1 study (1/-) | 56.9 % | NA | not evaluable | | non important | - |
| Nausea AE (grade 3-4) | 0.70 [0.01, 37.74] | | < 1 | | 0% | 1 study (1/-) | 56.9 % | NA | not evaluable | | non important | - |
| Neutropenia AE (grade 3-4) | 3.07 [0.13, 74.70] | | < 1 | | 0% | 1 study (1/-) | 24.9 % | NA | not evaluable | | non important | - |
| Pneumonia AE (grade 3-4) | 3.07 [0.13, 74.70] | | < 1 | | 0% | 1 study (1/-) | 24.9 % | NA | not evaluable | | non important | - |
| Pruritus AE (grade 3-4) | 0.70 [0.01, 37.74] | | < 1 | | 0% | 1 study (1/-) | 56.9 % | NA | not evaluable | | non important | - |
| Rash AE (grade 3-4) | 0.70 [0.01, 37.74] | | < 1 | | 0% | 1 study (1/-) | 56.9 % | NA | not evaluable | | non important | - |
| Stomatitis AE (grade 3-4) | 0.70 [0.01, 37.74] | | < 1 | | 0% | 1 study (1/-) | 56.9 % | NA | not evaluable | | non important | - |
